Open AccessDevelopment of [89Zr]ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancer
Author(s) -
Alessandra Cavaliere,
Song Sun,
Supum Lee,
Jacob Bodner,
Ziqi Li,
Yiyun Huang,
Sheri L. Moores,
Bernadette Marquez-Nostra
Publication year - 2020
Publication title -
european journal of nuclear medicine and molecular imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.313
H-Index - 163
eISSN - 1619-7089
pISSN - 1619-7070
DOI - 10.1007/s00259-020-04978-6
Subject(s) - triple negative breast cancer , epidermal growth factor receptor , biodistribution , cancer research , medicine , c met , breast cancer , in vivo , targeted therapy , cancer , lung cancer , radioligand , antibody , receptor , pathology , hepatocyte growth factor , immunology , biology , microbiology and biotechnology
Amivantamab is a novel bispecific antibody that simultaneously targets the epidermal growth factor receptor (EGFR) and the hepatocyte growth factor receptor (HGFR/c-MET) that are overexpressed in several types of cancer including triple-negative breast cancer (TNBC). Targeting both receptors simultaneously can overcome resistance to mono-targeted therapy. The purpose of this study is to develop 89 Zr-labeled amivantamab as a potential companion diagnostic imaging agent to amivantamab therapy using various preclinical models of TNBC for evaluation.